BackBoundless Bio Overview
Boundless Bio Inc.

Boundless Bio Discounted Cash Flow

Is BOLD undervalued? Intrinsic value estimate stands at $-1.4.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$-1.39

Current Fair Value

$-1.39
↓ 149.3% Downside

Overvalued by 149.3% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

Boundless Bio (BOLD) FAQ

Boundless Bio (BOLD) currently reports a DCF fair value of $-1.4. Use the charts on this page to explore Boundless Bio's DCF fair value history and peer comparisons.

Boundless Bio's discounted cash flow (DCF) fair value estimate is $-1.4, about 149.3% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $-1.4, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Boundless Bio, and consider following BOLD for alerts when major investors trade the stock.